Date de publication: 8 novembre 2024
Promoteur – Intermédiaire Financier
PHARMATHEN SA - INDUSTRIAL AND COMMERCIAL COMPANY OF PHARMACEUTICALS AND COSMETICSLieu
Description
The project will finance the promoter's Research and Development (R&D) investments in the period 2025-2028.
Objectifs
The aim is to support Pharmathen's R&D expenditures.
Secteur(s)
- Industrie - Industrie manufacturière
Montant BEI envisagé (montant approximatif)
EUR 100 million
Coût total (montant approximatif)
EUR 229 million
Aspects environnementaux
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, making use of existing laboratories Thus an Environmental Impact Assessment (EIA) is not foreseen. The RDI activities do not fall under the Annexes of the EIA Directive 2011/92/EU as amended by Directive 2014/52/EU. The full environmental details will however be investigated by the Bank's services during the due diligence stage.
Passation des marchés
The Promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the Promoter is subject to the EU public procurement legislation then the Bank would duly inform the Commission Services and would require the Promoter to apply those rules.
Statut
À l'examen - 24/09/2024
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).